ASH news is flying around the internet! Most is anticipatory; early teasers of technical presentations still to come. Most myeloma related news here pops Sunday and Monday. That's why I didn't arrive until today. Here's something interesting. I hadn't heard much about a preclinical drug, ACY-1215 since I wrote several posts about it in 2013.
Ever take Revlimid? Wonder where the tens of thousands of dollars that Medicare or your private insurance company pays for it goes each month? To finance speculative acquisitions of small, start-up pharmaceutical companies, of course! A few short weeks after acquiring the rights to one of the hottest yet unproven anti-myeloma therapy agents, MorphoSys' MOR202,